4E Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- 4E Therapeutics's estimated annual revenue is currently $603k per year.
- 4E Therapeutics's estimated revenue per employee is $100,500
- 4E Therapeutics's total funding is $7.2M.
Employee Data
- 4E Therapeutics has 6 Employees.
- 4E Therapeutics grew their employee count by 0% last year.
4E Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Co-Founder | Reveal Email/Phone |
4 | Co-Founder, President & Chairman | Reveal Email/Phone |
5 | Co-Founder | Reveal Email/Phone |
6 | VP Drug Development | Reveal Email/Phone |
7 | Director Operations (Business) | Reveal Email/Phone |
4E Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $32.4M | 161 | 20% | N/A | N/A |
#2 | $16.3M | 81 | 7% | N/A | N/A |
#3 | $18.7M | 93 | 16% | N/A | N/A |
#4 | $62.5M | 0 | N/A | N/A | N/A |
#5 | $12.3M | 61 | 7% | N/A | N/A |
#6 | $184.1M | 916 | 38% | $50M | N/A |
#7 | $27.7M | 138 | 8% | N/A | N/A |
#8 | $112.4M | 559 | 8% | N/A | N/A |
#9 | $12.5M | 62 | 11% | N/A | N/A |
#10 | $8M | 40 | 14% | N/A | N/A |
What Is 4E Therapeutics?
$7.2M
Total Funding
6
Number of Employees
$603k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
4E Therapeutics News
2022-04-20 - Structural insights into sphingosine-1-phosphate receptor ...
Sphingosine-1-phosphate (S1P) receptors are valid therapeutic targets to treat ... 4E). In the deep mode, the carboxyl group of CBP-307 forms extensive...
2022-04-06 - Massively parallel, computationally guided design of a ...
Proteins have shown promise as therapeutics and diagnostics, ... 4E). The former conformation is observed in the crystal structure of CPG2 reported here (SI...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.1M | 6 | -33% | $47.6M |
#2 | $0.8M | 6 | -33% | N/A |
#3 | $0.8M | 6 | -25% | N/A |
#4 | $0.1M | 6 | -25% | $50M |
#5 | N/A | 6 | N/A | N/A |